The FDA this week post­ed an un­ti­tled let­ter sent Oct. 17 to Chi­na-based ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API) ...
Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most ...
Am­gen and As­traZeneca said on Fri­day that their asth­ma drug Tezspire re­duced nasal con­ges­tion and the size of nasal ...
GSK is leaving the biopharma trade group BIO, a spokesperson confirmed, the latest large pharma to back out of the group.
Nkarta is punting development of a natural killer cell therapy in cancer to focus instead on the same candidate's prospects ...
In another sign that biopharma companies are slowing their early R&D efforts, Charles River Laboratories is shuttering more than a dozen sites. The service provider is working on “consolidating ...
Alan Bash is joining Legend Biotech as its president of Carvykti, an unconventional, newly-created role to oversee the ...
Athira Pharma has shelved a daily drug for Alzheimer’s after a mid-stage flop, instead shifting its focus to an oral ...
Stephen Squinto, recruited by JP Morgan a few years ago to head up its Life Sciences Private Capital team, is raising a ...
The head of AstraZeneca’s operations in China has been detained by authorities there, the company confirmed. Prior to his ...
California voters supported a state ballot measure on Tuesday that would increase oversight around the 340B federal drug ...
Gilead said its Covid-19 antiviral Veklury had $692 million in third-quarter sales, far more than the $270 million Wall ...